For the reasons described in the 6/29/2015 edition of Smart Tech 50 Weekly Movers, we are adding Meridian Biosciences (VIVO) to the Medical Profits portfolio with a buy limit price of $19 and a stop loss at $16. Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
Is Facebook the perfect business model, or a disaster in the making? Read More
Since launching the Maximum Income for Retirees portfolio late last year we have received positive feedback from subscribers seeking greater investment income. Originally we limited each of the three sectors groups – REIT (Real Estate Investment Trust), MLP (Master Limited Partnership), and BDC (Business Development Company) – to four holdings… Read More
As much as we loved the idea of making trading recommendations based on short term opportunities we saw in the tech sector, the feedback we got from our subscribers is that they would prefer a longer term, and more focused portfolio. For that reason, we are renaming our Equity Trades… Read More
As much as we loved the idea of making trading recommendations based on short term opportunities we saw in the tech sector, the feedback we got from our subscribers is that they would prefer a longer term, and more focused portfolio. For that reason, we are renaming our Equity Trades… Read More
As much as we loved the idea of making trading recommendations based on short term opportunities we saw in the tech sector, the feedback we got from our subscribers is that they would prefer a longer term, and more focused portfolio. For that reason, we are renaming our Equity Trades… Read More
All told, over 2.5 million Americans are candidates for exoskeletons currently available or already under development. With only about 250 sold to date – and sales accelerating each month – the potential is virtually limitless. Read More
All told, over 2.5 million Americans are candidates for exoskeletons currently available or already under development. With only about 250 sold to date – and sales accelerating each month – the potential is virtually limitless. Read More
- June 15, 2015
-
Download Issue
Making money investing in the tech sector is not as easy as it may seem. While the mainstream media spends most of its time talking about the companies that have already become industry heavyweights, it spends very little time discussing those that have fallen by the wayside. Of course, as… Read More
Making money investing in the tech sector is not as easy as it may seem. While the mainstream media spends most of its time talking about the companies that have already become industry heavyweights, it spends very little time discussing those that have fallen by the wayside. Of course, as… Read More